Pfizer’s Growth Rate and Estimates
Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.
Nov. 20 2020, Updated 2:10 p.m. ET
Pfizer’s revenues and EPS
Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.
The above chart compares Pfizer’s revenue and EPS growth rate since the first quarter of 2017 with the third-quarter estimates.
Revenue growth rate
Pfizer reported ~4.4% revenue growth in the second quarter. The reported revenues increased to ~$13.5 billion during the quarter—compared to $12.9 billion during the second quarter of 2017.
The revenue growth was driven by the Innovative Health segment’s strong performance. The revenue growth was partially offset by lower product sales in the Essential Health segment.
Analysts expect the revenues to increase ~2.9% to $13.5 billion during the third quarter—compared to revenues of $13.2 billion during the third quarter of 2017.
EPS growth rate
Pfizer reported ~20.9% growth in its EPS in the second quarter. The adjusted EPS increased to $0.81 during the quarter—compared to the adjusted EPS of $0.67 in the second quarter of 2017.
The reported EPS was $0.65 during the second quarter, which was higher than the reported EPS of $0.51 during the second quarter of 2017. In the past two years, the lowest EPS reported was $0.14 during the fourth quarter of 2016. The highest EPS reported was $0.65 during the second quarter.
Analysts expect the EPS to increase to $0.58 during the third quarter—23.4% growth compared to the EPS of $0.47 during the third quarter of 2017.
The iShares Evolved US Innovative Healthcare ETF (IEIH) holds 7.4% of its total investments in Pfizer, 9.8% in Johnson & Johnson (JNJ), 6.0% in Eli Lilly (LLY), and 4.4% in Celgene (CELG).
